Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need

Transfusion

Volumn 52, Issue 10, 2012, Pages 2131-2138

  Goldberg, Stuart L ^a   Chen, Er ^a   Sasane, Medha ^a   Paley, Carole ^a   Guo, Amy ^a   Laouri, Marianne ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONOXINOL 9;

AGED; ARTICLE; BACTEREMIA; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; DYSPNEA; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART ARRHYTHMIA; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICARE; MORTALITY; MYELODYSPLASTIC SYNDROME; PNEUMONIA; PREVALENCE; RETROSPECTIVE STUDY; SEPSIS;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; BLOOD TRANSFUSION; COMORBIDITY; DATABASES, FACTUAL; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HEALTH SERVICES NEEDS AND DEMAND; HEMATOPOIETIC CELL GROWTH FACTORS; HOSPITALIZATION; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MEDICARE; MYELODYSPLASTIC SYNDROMES; OFFICE VISITS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84868303220     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03626.x     Document Type: Article

References (16)

1. TM)-Myelodysplastic Syndrome, Version 2. 2011. [cited 2012 Mar 21]. Available from: URL: http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp
2. Greenberg PL,. Current therapeutic approaches for patients with myelodysplastic syndromes. Br J Haematol 2010; 150: 131-43.
3. Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, Laouri M,. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 2010; 28: 2847-52.
4. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, Edwards BK, List AF,. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008; 112: 45-52.
5. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J,. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-88.
6. Malcovati L,. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 2007; 31 Suppl 3: S2-6.
7. Sanz G, Nomdedeu B, Such E, Bernal T, Belkaid M, Ardanaz MA, Marco V, Pedro C, Ramos F, del Cañizo NC, Luño E, Cobo F, Carbonell F, Gomez V, Muñoz JA, Amigo ML, Bailen A, Bonanad S, Tormo M, Andreu R, Arrizabalaga B, Arilla MJ, Bueno J, Requena MJ, Cervera J, et al,. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [abstract]. Blood 2008; 112: 640.
8. Gupta P, LeRoy SC, Luikart SD, Bateman A, Morrison VA,. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res 1999; 23: 953-9.
9. Frytak JR, Henk HJ, De Castro CM, Halpern R, Nelson M,. Estimation of economic costs associated with transfusion dependence in adults with MDS. Curr Med Res Opin 2009; 25: 1941-51.
10. Goss TF, Szende A, Schaefer C, Totten PJ, Knight R, Jädersten M, Hellström-Lindberg E, List AF,. Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. Cancer Control 2006; 13 Suppl: 17-25.
11. Pan F, Peng S, Fleurence R, Linnehan JE, Knopf K, Kim E,. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective. Clin Ther 2010; 32: 2444-56.
12. Greenberg PL, Cosler LE, Ferro SA, Lyman GH,. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. J Natl Compr Canc Netw 2008; 6: 942-53.
13. Fisher ES, Whaley FS, Krushat WM, Malenka DJ, Fleming C, Baron JA, Hsia DC,. The accuracy of Medicare's hospital claims data: progress has been made, but problems remain. Am J Public Health 1992; 82: 243-8.
14. Jollis JG, Ancukiewicz M, DeLong ER, Pryor DB, Muhlbaier LH, Mark DB,. Discordance of databases designed for claims payment versus clinical information systems. Implications for outcomes research. Ann Intern Med 1993; 119: 844-50.
15. Pereira A, Nomdedeu M, Aguilar JL, Belkaid M, Carriõ A, Cobo F, Costa D, Rozman M, Sanz C, Nomdedeu B,. Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support. Am J Hematol 2011; 86: 245-50.
16. Greenberg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, DeCastro CM, Deeg HJ, Erba HP, Foran JM, Garcia-Manero G, Gore SD, Head D, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Saba HI, Shami PJ, Spiers K, Stone RM, Tallman MS, Westervelt P,. Myelodysplastic syndromes. J Natl Compr Canc Netw 2008; 6: 902-26.